Statins: Definitive Translational Research-Reference-Cited by-同舟云学术

Statins: Definitive Translational Research

Published:2014-01 Issue:S1 Volume:20 Page:S20-S23
ISSN:1076-1551
Container-title:Molecular Medicine
language:en
Short-container-title:Mol Med

Author:

Grundy Scott M.

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.2119/molmed.2014.00194.pdf

Reference57 articles.

1. Anitschkow NN, Chalatov S. (1913) Ueber experimentelle Choleserinsteatose und ihre Bedeutung fur die Entstehung einiger pathologischer Prozesse [On experimental cholesterol steatosis and its significance for the development of some pathological processes]. Zentralbl Allg Pathol 24:1–9.

2. Gofman JW, et al. (1950) The role of lipids and lipoproteins in atherosclerosis. Science. 111:166–71.

3. Steinberg D. (2005) Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia. J. Lipid Res. 46:2037–51.

4. Fuster V. (1995) Elucidation of the role of plaque instability and rupture in acute coronary events. Am. J. Cardiol. 76:24C–33C.

5. Brown MS, Goldstein JL. (1986) A receptor-mediated pathway for cholesterol homeostasis. Science. 232:34–47.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024;Obesity Pillars;2024-06

2. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024;Journal of Clinical Lipidology;2024-05

3. Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol‐lowering treatments?;European Journal of Clinical Investigation;2022-03-24

4. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism;Arteriosclerosis, Thrombosis, and Vascular Biology;2018-07

5. Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte;Clinical Science;2017-04-19